News
IMDX
5.40
-3.40%
-0.19
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
Barchart · 6d ago
Weekly Report: what happened at IMDX last week (0615-0619)?
Weekly Report · 6d ago
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
TipRanks · 06/17 21:31
Insight Molecular Diagnostics shareholders approve 1,750,000-share increase to equity plan
PUBT · 06/17 20:06
Insight Molecular Diagnostics says Clinical Chemistry study shows 99.2% agreement between GraftAssure and rival NGS dd-cfDNA test at 0.5% threshold
PUBT · 06/16 20:05
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
Barchart · 06/16 15:05
Weekly Report: what happened at IMDX last week (0608-0612)?
Weekly Report · 06/15 10:40
Insight Molecular Diagnostics says study shows GraftAssure CM-Score lifts kidney transplant rejection PPV to 81%
PUBT · 06/11 20:17
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
Barchart · 06/11 15:17
Insight Molecular Diagnostics to showcase GraftAssure at American Transplant Congress
PUBT · 06/09 20:06
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
Barchart · 06/09 15:05
Weekly Report: what happened at IMDX last week (0601-0605)?
Weekly Report · 06/08 10:35
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/05 21:06
Weekly Report: what happened at IMDX last week (0525-0529)?
Weekly Report · 06/01 10:41
Weekly Report: what happened at IMDX last week (0518-0522)?
Weekly Report · 05/25 10:45
Insight Molecular Diagnostics Balances Progress and Cash Burn
TipRanks · 05/20 05:35
Weekly Report: what happened at IMDX last week (0511-0515)?
Weekly Report · 05/18 10:44
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (AQST), Sangamo Therapeutics (OtherSGMO) and Insight Molecular Diagnostics (IMDX)
TipRanks · 05/15 12:01
OncoCyte’s Earnings Call Maps Risky Path to Launch
TipRanks · 05/15 00:31
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)
TipRanks · 05/14 13:19
More
Webull provides a variety of real-time IMDX stock news. You can receive the latest news about Insight Molecular Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.